Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.999 USD | +1.74% | -0.04% | -45.82% |
02:04pm | Top Premarket Gainers | MT |
May. 13 | Barinthus Biotherapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Number of employees: 130
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Immunotherapies and Vaccines
100.0
%
| 45 | 100.0 % | 1 | 100.0 % | -98.21% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom and United States
100.0
%
| 45 | 100.0 % | 1 | 100.0 % | -98.21% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
William Enright
CEO | Chief Executive Officer | 61 | 19-07-31 |
Gemma Brown
DFI | Director of Finance/CFO | 34 | 21-08-31 |
Nadège Pelletier
CTO | Chief Tech/Sci/R&D Officer | 46 | 23-01-31 |
Investor Relations Contact | - | 22-09-30 | |
Graham Griffiths
PRN | Corporate Officer/Principal | 45 | 17-09-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Karen Dawes
BRD | Director/Board Member | 72 | 21-02-28 |
William Enright
CEO | Chief Executive Officer | 61 | 19-07-31 |
Anne Phillips
BRD | Director/Board Member | 70 | 21-02-20 |
Robin Wright
CHM | Chairman | 59 | 18-09-30 |
Director/Board Member | 61 | 17-12-31 | |
Alex Hammacher
BRD | Director/Board Member | 43 | 19-12-31 |
Joseph Scheeren
BRD | Director/Board Member | 68 | 21-03-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 38,952,956 | 37,217,593 ( 95.54 %) | 0 | 47.72 % |
Stock B | 1 | 39,033,158 | 0 | 0 |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.82% | 76.7M | |
+56.13% | 59.34B | |
+42.83% | 40.24B | |
-5.28% | 39.88B | |
-5.56% | 28.55B | |
+16.40% | 27.26B | |
-20.49% | 19.23B | |
+33.23% | 12.61B | |
+3.04% | 12.49B | |
+24.37% | 12.28B |
- Stock Market
- Equities
- BRNS Stock
- Company Barinthus Biotherapeutics plc